The models are designed to predict someone’s risk of diabetes or stroke. A few might already have been used on patients.
An Excel-based actuarial model (1 million lives; 49% eligible; 10% treated) estimated semaglutide coverage could be ...
A Luxembourg-based start-up has raised $10 million to help the pharmaceutical sector exploit the power of AI to drive faster ...
A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again.
Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI to deploy the technology ...
Researchers at Toronto's Sinai Health have found that semaglutide—the active ingredient in popular weight loss drugs that ...
Tim Church, MD, PhD, MPH, explains that access to care—not willpower—is the central barrier to GLP-1 use, and says employer ...
People on GLP-1s experience low appetite, but it's still important they eat enough nutrients, Rob Hobson, a nutritionist and ...
A new agentic AI application aims to speed up drug development, helping bring new medical treatments to patients faster.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results